Brief: Tvardi Therapeutics Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% Placebo
08/01/2026 13:35
Jan 8 (Reuters) - Tvardi Therapeutics Inc TVRD.O: TVARDI THERAPEUTICS INC - TTI-101 SHOWS 9.4% FIBROSIS SCORE DECREASE VERSUS 2.4% PLACEBO TVARDI THERAPEUTICS INC - TOPLINE HEALTHY VOLUNTEER DATA FROM PHASE 1 STUDY OF NEXT-GENERATION STAT3 INHIBITOR, TTI-109, ON TRACK FOR H1 2026 Source text: ID:nGNX2MMRKZ Further company coverage: TVRD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tvardi Therapeutics
See all newsTvardi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tvardi Therapeutics Q2 net loss slightly lower estimates
Brief: Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:50 PM